BR112023018281A2 - Novo derivado de pirimidina que mostra efeito de inibição sobre o crescimento de células cancerígenas - Google Patents

Novo derivado de pirimidina que mostra efeito de inibição sobre o crescimento de células cancerígenas

Info

Publication number
BR112023018281A2
BR112023018281A2 BR112023018281A BR112023018281A BR112023018281A2 BR 112023018281 A2 BR112023018281 A2 BR 112023018281A2 BR 112023018281 A BR112023018281 A BR 112023018281A BR 112023018281 A BR112023018281 A BR 112023018281A BR 112023018281 A2 BR112023018281 A2 BR 112023018281A2
Authority
BR
Brazil
Prior art keywords
growth
inhibition effect
cancer cells
pyrimidine derivative
new pyrimidine
Prior art date
Application number
BR112023018281A
Other languages
English (en)
Inventor
Min Jeon Hye
Jung Kim Min
Seo Baek Min
Ho Lee Sun
Eun Kim Sung
Hyup Lee Yong
Jeong Kong Yun
Original Assignee
Oncobix Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Oncobix Co Ltd filed Critical Oncobix Co Ltd
Publication of BR112023018281A2 publication Critical patent/BR112023018281A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Abstract

novo derivado de pirimidina que mostra efeito de inibição sobre o crescimento de células cancerígenas. presente invenção se refere a um novo composto derivado de pirimidina.
BR112023018281A 2021-03-11 2022-03-11 Novo derivado de pirimidina que mostra efeito de inibição sobre o crescimento de células cancerígenas BR112023018281A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20210031948 2021-03-11
PCT/KR2022/003457 WO2022191664A1 (ko) 2021-03-11 2022-03-11 암세포 성장 억제 효과를 나타내는 신규한 피리미딘 유도체

Publications (1)

Publication Number Publication Date
BR112023018281A2 true BR112023018281A2 (pt) 2023-10-31

Family

ID=83226938

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023018281A BR112023018281A2 (pt) 2021-03-11 2022-03-11 Novo derivado de pirimidina que mostra efeito de inibição sobre o crescimento de células cancerígenas

Country Status (8)

Country Link
EP (1) EP4306518A1 (pt)
JP (1) JP2024509458A (pt)
KR (1) KR20220128590A (pt)
CN (1) CN117177968A (pt)
AU (1) AU2022232876A1 (pt)
BR (1) BR112023018281A2 (pt)
CA (1) CA3211588A1 (pt)
WO (1) WO2022191664A1 (pt)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2760794C (en) * 2009-05-05 2017-07-25 Dana Farber Cancer Institute Egfr inhibitors and methods of treating disorders
PE20151274A1 (es) * 2013-02-08 2015-09-12 Celgene Avilomics Res Inc Inhibidores de erk y sus usos
CN106928150B (zh) * 2015-12-31 2020-07-31 恩瑞生物医药科技（上海）有限公司 丙烯酰胺苯胺衍生物及其药学上的应用
CN107098887B (zh) * 2016-02-22 2019-08-09 复旦大学 嘧啶类化合物
CN106083736A (zh) * 2016-06-21 2016-11-09 郑州泰基鸿诺医药股份有限公司 一种嘧啶类化合物、egfr抑制剂及其应用

Also Published As

Publication number Publication date
AU2022232876A1 (en) 2023-09-21
EP4306518A1 (en) 2024-01-17
JP2024509458A (ja) 2024-03-01
KR20220128590A (ko) 2022-09-21
WO2022191664A1 (ko) 2022-09-15
CA3211588A1 (en) 2022-09-15
CN117177968A (zh) 2023-12-05

Similar Documents

Publication Publication Date Title
AR121997A2 (es) Forma cristalina de bencilbenceno inhibidor de sglt2
BR112019007612A2 (pt) conjugados de pirrolobenzodiazepina
CL2021000362A1 (es) Nuevos compuestos heterocíclicos como inhibidores de la monoacilglicerol lipasa
MA32794B1 (fr) Fabrication de moules de cellules solaires
UY39526A (es) Inhibidores de kras g12d
CU20120071A7 (es) DERIVADOS DE N1-PIRAZOLOESPIROCETONA ÚTILES COMO INHIBIDORES DE ACETIL-CoA CARBOXILASA
PE20210549A1 (es) Derivado de amino-metil piperidina como inhibidor de quinasa
CR20130233A (es) Derivados que quinazolin-4 (3h)-ona utilizados como inhibidores de pi3 cinaza
PE20151897A1 (es) Interfaz de sellado para un cierre de telecomunicaciones
HN2010002733A (es) Compuestos y composiciones como inhibidores de cinasa
DOP2010000183A (es) Derivados de itazol usados como inhibidores de pi 3-cinasa
AR074053A1 (es) Derivados de anilina-pirimidina sustituidos con sulfoximina como inhibidores de quinasas dependientes de ciclina (cdk), y composiciones farmaceuticas que los contienen
ECSP15032859A (es) Derivados de n-(sustituido)-5-fluoro-4-imino-3-metil-2-oxo-3,4-dihidropirimidin-1(2h)-carboxilato
CL2020003074A1 (es) Inhibidores de la vía de respuesta al estrés integrada.
PE20151589A1 (es) Proceso de fabricacion de vortioxetina
MY181228A (en) Triazine, piperidine and pyrrolidine based hindered amine light stabilizers
CO6460726A2 (es) Derivado de 5-hidroxi-pirimidin-4-carboxamida
WO2019023216A8 (en) INHIBITORS OF ROR GAMMA
ES2422733T3 (es) Pirimidilciclopentanos hidroxilados como inhibidores de proteínas cinasas AKT
BR112023018281A2 (pt) Novo derivado de pirimidina que mostra efeito de inibição sobre o crescimento de células cancerígenas
CL2023001049A1 (es) Procedimiento para la fabricación de compuestos orgánicos
BR112023017834A2 (pt) Inibidores de lrrk2 cinase macrocíclicos
CR20110589A (es) Compuestos y métodos para controlar hongos
BR112022006250A2 (pt) Compostos heterobicíclicos de arila como bloqueadores de canal de agitador de potássio kv1.3
BR112016006664A2 (pt) compostos para a inibição do crescimento celular desregulado